Circulating Tumor Cells, Erythroleukemia, Allograft, Liquid Biopsy, Cancer Treatment
Digital Object Identifier (DOI)
Murine erythroleukemia (MEL) cells are often employed as a model to dissect mechanisms of erythropoiesis and erythroleukemia in vitro. Here, an allograft model using MEL cells resulting in splenomegaly was established to develop a diagnostic model for isolation/quantification of metastatic cells, anti-cancer drug screening, and evaluation of the tumorigenic or metastatic potentials of molecules in vivo. In this animal model, circulating MEL cells from the blood stream were successfully isolated and quantified with an additional in vitro cultivation step. In terms of the molecular-pathological analysis, we were able to successfully evaluate the functional discrimination between methyl-CpG-binding domain 2 (Mbd2) and p66α in erythroid differentiation, and tumorigenic potential in spleen and blood stream of allograft model mice. In addition, we found that the number of circulating MEL cells in anti-cancer drug-treated mice was dose-dependently decreased. Our data demonstrate that the newly established allograft model is useful to dissect erythroleukemia pathologies and non-invasively provides valuable means for isolation of metastatic cells, screening of anti-cancer drugs, and evaluation of the tumorigenic potentials.
This work is licensed under a Creative Commons Attribution 4.0 License.
Was this content written or created while at USF?
Citation / Publisher Attribution
Cancers, v. 11, issue 11, art. 1707
Scholar Commons Citation
Kim, Min Young; Choi, Sungwoo; Lee, Seol Eui; Kim, Ji Sook; Son, Seung Han; Lim, Young Soo; Kim, Bang-Jin; Ryu, Buom-Yong; Uversky, Vladimir N.; Lee, Young Jin; and Kim, Chul Geun, "Development of a MEL Cell-derived Allograft Mouse Model for Cancer Research" (2019). Molecular Medicine Faculty Publications. 878.